Abstract Objective To study the clinical and laboratory features of macrophage activation syndrome (MAS) at the early stage of diagnosis, and to explore a method for early identification of MAS. Methods A retrospective analysis was performed for the demographic data, clinical and laboratory features, and treatment outcomes of 21 MAS patients. Results Of the 21 MAS patients, 14 had systemic juvenile idiopathic arthritis, 5 had Kawasaki disease (KD), and 2 had connective tissue disease (CTD) as primary diseases. The median time of MAS onset was 19 days. The KD patients had the shortest time of MAS onset, while the CTD patients had the longest onset time (P=0.009). The top 10 clinical symptoms were fever (95%), rash (86%), lymph node enlargement (67%), hemophagocytic phenomenon in bone marrow (63%), pulmonary disease (62%), serous effusion (62%), hepatomegaly (52%), cerebrospinal fluid abnormalities (50%), central nervous system damage (43%), and splenomegaly (38%). The median of hemoglobin level was lower than the normal value. The medians of C-reactive protein level and erythrocyte sedimentation rate were higher than the normal values. There were significant increases in serum ferritin, glutamic-pyruvic transaminase, aspartate aminotransferase, lactate dehydrogenase, and triglyceride. The median of fibrinogen level was lower than the normal value. There were significant increases in D-dimer, interleukin-6 (IL-6), interleukin-10 (IL-10), and interferon-γ (IFN-γ). Of the 21 patients, 20 were improved and discharged. Conclusions If patients with rheumatic disease have persistent fever, hepatic dysfunction, coagulation disorders, multiple organ impairment, significantly increased IL-10 and IFN-γ, and a persistent increase in serum ferritin, the development of MAS should be considered.
Stéphan JL,Koné-PautI,Galambrun C,et al.Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients[J].Rheumatology (Oxford), 2001,40(11):1285-1292.
Wang W,Gong F,Zhu W,et al.Macrophage activation syndrome in Kawasaki disease:more common than we thought[J].Semin Arthritis Rheum,2015,44(4):405-410.
[6]
Parodi A,Davì S,Pringe AB,et al.Macrophage activation syndrome in juvenile systemic lupus erythematosus:a multinational multicenter study of thirty-eight patients[J]. Arthritis Rheum,2009,60(11):3388-3399.
[7]
Behrens EM,Beukelman T,Paessler M,et al.Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis[J].J Rheumatol,2007,34(5):1133- 1138.
[8]
Bleesing J,Prada A,Siegel DM,et al.The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated newonset systemic juvenile idiopathic arthritis[J].Arthritis Rheum, 2007,56(3):965-971.
[9]
Minoia F,Davì S,Horne A,et al.Clinical features,treatment, and outcome of macrophage activation syndromecomplicating systemic juvenile idiopathic arthritis:a multinational, multicenter study of 362 patients[J].Arthritis Rheumatol,2014, 66(11):3160-3169.
[10]
Kostik MM,Dubko MF,Masalova VV,et al.Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis[J].Semin Arthritis Rheum,2015,44(4):417- 422.
Henter JI,Horne A,Aricó M,et al.HLH-2004:Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J].Pediatr Blood Cancer,2007,48(2):124-131.
[18]
Cron RQ,Davi S,Minoia F,et al.Clinical features and correct diagnosis of macrophage activation syndrome[J].Expert Rev Clin Immunol,2015,11(9):1043-1053.
[19]
Ravelli A,Minoia F,Davì S,et al.2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis:A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative[J].Ann Rheum Dis,2016,75(3):481-489.
[20]
Assari R,Ziaee V,Mirmohammadsadeghi A,et al.Dynamic changes,cut-off points,sensitivity,and specificity of laboratory data to differentiate macrophage activation syndrome from active disease[J].Dis Markers,2015,2015:424381.
[21]
Schulert GS,Grom AA.Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies[J].Annu Rev Med,2015,66:145-159.
[22]
Ravelli A,Grom AA,Behrens EM,et al.Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis,genetics,pathophysiology and treatment[J].Genes Immun,2012,13(4):289-298.
Yokota S,Itoh Y,Morio T,et al.Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with Tocilizumab[J].J Rheumatol,2015,42(4): 712-722.
